Sponsor

Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz KöR

Germany Langenbeckstrasse 1, Oberstadt, 55131 Mainz, Germany

About the sponsor

Clinical research at Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz includes treatment strategies for small cell lung cancer, non-small cell lung cancer with EGFR alterations, and advanced neuroendocrine neoplasias G3.

Immunotherapy in lung cancer
Targeted therapy for EGFR-mutated disease
Advanced neuroendocrine tumor management

The sponsor’s trial portfolio in this area also covers combinations of systemic and local treatments for disease control and progression management.

About Specializations

Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz KöR runs clinical trials in conditions such as Rectal cancer stage III, Rectal cancer stage II, Osteoarthritis, Mantle cell lymphoma, among others.

Recruiting now

Ongoing trials

Clinical trials run by this sponsor – those enrolling participants first.

Quick filters

7 clinical trials

Rectal cancer stage III+1

Recruiting

Study comparing treatment with or without tislelizumab for patients with locally advanced rectal cancer to see if surgery can be avoided

InvestigationalNo placebo

Study comparing treatment with or without tislelizumab for patients with locally advanced rectal cancer to see if surgery can be avoided

InvestigationalNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Tislelizumab
Sponsor:Rabin Medical Center

Contact Research Centre

Osteoarthritis

Recruiting

Study on Shortened Anticoagulation with Rivaroxaban for Blood Clot Prevention in Patients Undergoing Hip Replacement Surgery

Investigational

Study on Shortened Anticoagulation with Rivaroxaban for Blood Clot Prevention in Patients Undergoing Hip Replacement Surgery

Investigational

Austria

Participants:18–64 years · 65+ years
Substances:Rivaroxaban
Sponsor:Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz KöR

Contact Research Centre

Mantle cell lymphoma

Recruiting

Study of Venetoclax, Ibrutinib, and Rituximab or Bendamustine Combination for Patients with Untreated Mantle Cell Lymphoma Not Suitable for High-Dose Therapy

Registered drugNo placebo